tirzepatide pdufa FDA Grants a New Indication for Obesity Management Does Tirzepatide Help With Inflammation?

People with obesity and insulin resistance typically have poor metabolic flexibility

Restaurant portions are huge anyway - this is your excuse to stop pretending you need to clean your plate

16 Cardiovascular outcomes The cardiovascular outcomes trial for tirzepatide, SURPASS-CVOT, is an active-comparator study versus dulaglutide 1.5 mg weekly and is ongoing

The only difference is the FDA-approved indication, not the dosing protocol

Patients taking oral contraceptives should use backup contraception for 4 weeks after tirzepatide initiation and after each dose increase, as delayed gastric emptying may reduce contraceptive absorption and effectiveness

Martinelli, S